Abstract
Background: : In 2016, California updated its prescription drug monitoring program (PDMP), adding two key features: automated proactive reports to prescribers and mandatory registration for prescribers and pharmacists. The effects of these changes on prescribing patterns have not yet been examined. We aimed to evaluate the joint effect of these two PDMP features on county-level prescribing practices in California. Methods: : Using county-level quarterly data from 2012 to 2017, we estimated the absolute change associated with the implementation of these two PDMP features in seven prescribing indicators in California versus a control group comprising counties in Florida and Washington: opioid prescription rate per 1000 residents; patients’ mean daily opioid dosage in milligrams of morphine equivalents[MME]; prescribers’ mean daily MME prescribed; prescribers’ mean number of opioid prescriptions per day; percentage of patients getting >90 MME/day; percentage of days with overlapping prescriptions for opioids and benzodiazepines; multiple opioid provider episodes per 100,000 residents. Results: : Proactive reports and mandatory registration were associated with a 7.7 MME decrease in patients’ mean daily opioid dose (95 %CI: -11.4, -2.9); a 1.8 decrease in the percentage of patients prescribed high-dose opioids (95 %CI: -2.3, -0.9); and a 6.3 MME decrease in prescribers’ mean daily dose prescribed (95 %CI: -10.0, -1.3). Conclusions: : California's implementation of these two PDMP features was associated with decreases in the total quantity of opioid MMEs prescribed, and indicators of patients prescribed high-dose opioids compared to states that had PDMP's without these features. Rates of opioid prescribing and other high-risk prescribing patterns remained unchanged.
| Original language | English |
|---|---|
| Article number | 108405 |
| Journal | Drug and Alcohol Dependence |
| Volume | 218 |
| DOIs | |
| State | Published - Jan 1 2021 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier B.V.
Funding
This work was supported by the Bureau of Justice Assistance grant 2015-PM-BX-K001 and the Centers for Disease Control and Prevention grant 1U17CE002747 . ACC was supporter by FONDECYT regular grant 1191282 , and SH was supported by the National Institutes of Health grant K23DA043052 .
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | |
| Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse | K23DA043052 |
| Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse | |
| Centers for Disease Control and Prevention | 1U17CE002747 |
| Centers for Disease Control and Prevention | |
| Bureau of Justice Assistance | 2015-PM-BX-K001 |
| Bureau of Justice Assistance | |
| Fondo Nacional de Desarrollo Científico y Tecnológico | 1191282 |
| Fondo Nacional de Desarrollo Científico y Tecnológico |
Keywords
- California
- Opioid analgesics
- Prescribing practices
- Prescription drug monitoring program
- Program evaluation
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)